Today, with the introduction of interferon-free directacting antivirals and outstanding progresses in the prevention, diagnosis and treatment of hepatitis C virus (HCV) infection, the elimination of HCV infection seems more achievable. A further challenge is continued transmission of HCV infection in high-risk population specially injecting drug users (IDUs) as the major reservoir of HCV infection. Considering the fact that most of these infections remain undiagnosed, unidentified HCVinfected IDUs are potential sources for the rapid spread of HCV in the community. The continuous increase in the number of IDUs along with the rising prevalence of HCV infection among young IDUs is harbinger of a forthcoming public health dilemma, presenting a serious challenge to control transmission of HCV infection. Even the changes in HCV genotype distribution attributed to injecting drug use confirm this issue. These circumstances create a strong demand for timely diagnosis and proper treatment of HCV-infected patients through risk-based screening to mitigate the risk of HCV transmission in the IDUs community and, consequently, in the society. Meanwhile, raising general awareness of HCV infection, diagnosis and treatment through public education should be the core activity of any harm reduction intervention, as the root cause of failure in control of HCV infection has been lack of awareness among young drug takers. In addition, effective prevention, comprehensive screening programs with a specific focus on high-risk population, accessibility to the new anti-HCV treatment regimens and public education should be considered as the top priorities of any health policy decision to eliminate HCV infection.
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the well-characterized symptoms of jaundice. These symptoms might appear from 3 to 12 w�� after �eing w�� after �eing after �eing infected. The clinical symptoms of chronic HCV infection might ta��e decades to develop, and they are usually indicative of an advanced liver disease [13] [14] [15] . The long-term chronic HCV infection is capa�le of causing some extra hepatic manifestations with serious consequences, such as glomerulonephritis, dia�etes mellitus, thyroid disorders, porphyria cutaneous tarda, mixed cryoglo�ulinemia, lichen planus, and B cell lymphoproliferative disorders [16] [17] [18] [19] [20] [21] . These extrahepatic complications might outshine the hepatic manifestations of HCV infection, and the presence of HCV infection might �e overloo��ed, paving the way for the silent development of advanced liver disease. Therefore, the possi�le role of HCV in the development of extrahepatic manifestations merits further attention.
Due to genomic heterogeneity, there are 7 major genotypes and over 67 su�types of HCV [1, 22, 23] . HCV genotype distri�ution varies �y the route of transmission and geographical location [24, 25] . In addition, pathogenicity, response to antiviral therapy and the duration of treatment can �e influenced �y different HCV genotypes [5, 24, 26] . The genotypes 1, 2 and 3 show a widespread distri�ution in almost all parts of the world. HCV genotype 4 has �een traditionally restricted to a few countries in the Middle East and Africa and is more prevalent in Saudi Ara�ia, Bahrain, Jordan, Egypt and Ethiopia [1, 27, 28] . HCV genotype 5, 6 and 7 have �een reported in South Africa, South East Asia and Central Africa, respectively [11, 29, 30] (Figure 1 ).
Genotype 1 is more prevalent among patients with history of �lood and �lood products transfusion, surgery, and dental procedure [24, 25, 27] . Infection with HCV genotype 2 is mainly associated with nosocomial transmission and prior dental treatment [1, 22] . Genotype 3 is frequently found in the intravenous drug user communities and in those with history of tattooing and piercing [24, 31, 32] . Genotype 4 is mainly transmitted through high-ris�� sexual practices, especially among homosexual males, and intravenous drug use [1, 22] . Infection with HCV genotype 3 is associated with a more rapid progression of fi�rosis, a higher degree of steatosis, and a higher incidence of cirrhosis and hepatocellular carcinoma [1, 22, 31, 33] . Spontaneous clearance is more often o�served in infection with HCV genotype 1, while if patients remain HCV RNA positive, the disease progresses in a more aggressive manner than the other genotypes [11] . Genotypes 1 and 4 are associated with lower response rates and higher treatment duration in response to interferon (IFN) and ri�avirin (RBV) com�ination therapy as compared to genotypes 2 and 3 [6, 24, 34] .
PROGRESSES IN THE MANAGEMENT OF HCV INFECTION
In addition to IFN-�ased therapies, the direct-acting antivirals (DAAs) have been developed, which specifically restricted accessibility to diagnostic approaches and appropriate antiviral treatments in the injecting drug users (IDUs) community are the root cause of failure in control of HCV infection among IDUs. These circumstances create a strong demand for timely diagnosis and proper treatment of HCV-infected patients as well as raising general awareness of HCV infection through public education to mitigate the risk of HCV transmission.
INTRODUCTION
With a glo�al prevalence rate of 2.8%, equating to over 185 million infections, and more than 350000 deaths annually, hepatitis C virus (HCV) infection is undou�tedly considered a major pu�lic health pro�lem [1] . Glo�ally, an estimated 3 million to 4 million new cases of HCV infection emerge every year [1] . Furthermore, the HCVrelated mortality is increasing and HCV infection is projected to �e the most important leading cause of viral hepatitis-related mortality in the near future [1, 2] . Apparently, the management of HCV infection faces several challenges. These challenges merit further attention if elimination of HCV infection is aimed to �e achieved.
HCV
HCV is a mem�er of the family Flaviviridae and the genus Hepacivirus. The HCV genome is a positive-stranded RNA, which encodes a core protein (C), two envelope glycoproteins (E1 and E2), and several non-structural proteins (NS1, NS2, NS3, NS4A, NS4B, NS5A and NS5B) [3, 4] . This enveloped positive-stranded RNA virus is usually acquired through exposure to infected �lood. This might happen through transfusion of �lood and �lood products, surgery, organ transplantation, intravenous drug use, tattooing, hemodialysis, unsafe injection practices, mother to fetus, and sexual intercourse [5] [6] [7] [8] . However, sexual transmission of HCV is less common and most often o�served among men who have sex with men and HIV-infected patients [9, 10] . HCV is the causative agents of hepatitis C infection. This infection is characterized �y an acute or chronic course in the host. The complications are preliminary asymptomatic, mild or severe, which spontaneously clear or slowly progress to chronic liver disease, cirrhosis and finally hepatocellular carcinoma (HCC) within a�out 20 years [11, 12] . The clinical symptoms of acute HCV infection might include fever, fatigue, malaise, and gastrointestinal symptoms such as anorexia, nausea, vomiting, right upper quadrant pain, dar�� urine, greycolored stool, and yellow s��in and sclera of the eyes, inhi�it the function of viral proteins that are essential for viral replication [4, 37, 38] . These DAAs include NS3/4A protease inhi�itors, NS5A replication complex inhi�itors, nucleoside NS5B polymerase inhi�itors, and nonnucleoside NS5B polymerase inhi�itors (Ta�le 1) [39] [40] [41] [42] [43] . These novel antiviral drugs, despite having considera�le advantages over conventional IFN-�ased therapy, suffer from the resistance-associated mutations, which occur naturally during the replication of the virus and select under the pressure of DAAs. The emergence of HCV resistance-associated variants (RAVs) decreases the suscepti�ility to DAAs and finally results in treatment failure [38, [44] [45] [46] . Assessment of resistance su�stitutions at pretreatment �aseline in patients candidate for DAA therapy seems to �e the �est option to optimize first-line therapeutic strategies, to avoid the fitness of resistant variants as the predominant viral population and to prevent DAA failure due to �aseline resistant variants. In addition, failing DAA-�ased therapy should �e discontinued as soon as possi�le to avoid an increase in the frequency of RAVs, to preserve HCV re-treatment options. Finally, development of nextgeneration DAAs with higher resistance �arrier is strongly recommended [45, 47] . Telaprevir and �oceprevir are not recommended �y WHO due to the frequent adverse effects and low cure rates [79] . Prior to the treatment, the infected individuals need to be identified. HCV infection is described by the presence of anti-HCV anti�odies and HCV-RNA in plasma or serum with either elevated or normal levels of liver enzymes [29] . Anti-HCV anti�odies are detected �y using serological screening tests, including enzyme lin��ed immunosor�ent assay and recom�inant immuno�lot assay. Detection of anti-HCV anti�odies indicates current or past HCV infection. An additional test called HCV RNA test or reverse transcriptase polymerase chain reaction assay (RT-PCR) is needed to determine if a person is currently infected with HCV [17, [80] [81] [82] . However, those infected individuals with undetecta�le levels of HCV-RNA in serum or plasma might remain undiagnosed. In this condition, HCV-RNA can �e detected in peripheral �lood mononuclear cells (PBMCs) specimens, liver �iopsies, and ultracentrifugated serum samples [81, 83] . Serological screening tests might �e negative or positive in these patients. This ��ind of infection is defined as occult HCV infection, which is a serious threat to �lood safety [84, 85] . Since, despite having undetecta�le level of HCV RNA, �lood and �lood products are potentially infectious [84, 86] . In fact, the presence of �lood donors with occult HCV infection can increase the ris�� of HCV transmission through �lood transfusion and therefore is a potential source of HCV transmission in the society [87] . Despite having appropriate antiviral treatments and diagnostic approaches, diagnosis rate and access to treatment is considera�ly low especially in resourcelimited settings. Perhaps the most promising strategy to control HCV infection is the development of a prophylactic vaccine [88, 89] . Several vaccine candidates against HCV have �een developed so far, including recom�inant protein vaccine, peptide-�ased vaccine, [1, 11, 30, 35, 36] . [29, 88, [90] [91] [92] [93] [94] [95] [96] . The currently developed vaccines against HCV, despite inducing strong humoral and cellular immune responses in preclinical animal models or clinical trials in humans, have not �een approved for use in human �eings [89, 90, 97] . The reason is high genomic diversity of HCV and viral escape from immune responses [88, 90, 93, 98, 99] . Targeting the conserved regions within HCV proteins might help to overcome this genetic varia�ility [100] . In the a�sence of an approved prophylactic vaccine for hepatitis C, reducing exposure to HCV through prevention seems to �e the �est option. This can �e achieved through routine screening of donated �lood for HCV mar��ers, providing safe medical procedures, promoting ris��-reduction counseling and services for at ris�� population, increasing pu�lic awareness and offering regular HCV testing to high-ris�� populations with the goal of �rea��ing the cycle of HCV transmission in the society [7, 9, 82, 133] . Despite the so-called improvements in the management of HCV infection, still a long way is ahead to achieve a world free of HCV infection. Here, the remaining challenges to eliminating HCV infection will �e discussed.
REMAINING CHALLENGES TO ELIMINATING HCV INFECTION
For many years, IFN-�ased therapy, despite having frequent side effects, poor tolerability, suboptimal efficacy and prolonged treatment course, was recommended as the standard treatment for HCV infection [134, 135] . Introduction of IFN-free DAAs has solved most of these pro�lems in the treatment course of HCV infection. Switch the HCV treatment regimens from IFN-�ased therapy to DAA therapy is a desira�le approach, yet encounter practical �arriers such as high price and the restricted accessi�ility of DAAs [135] [136] [137] [138] . Most of the time, the cost of antivirals rather than their effectiveness is the main driver in the treatment decisions. The use of these DAAs is far beyond the financial means of the most-inneed patients especially those who are IFN-intolerant or non-responder. While, equity in health demands that all patients with every socioeconomic status have equita�le access to these treatment regimens. Currently, reducing treatment costs and providing DAAs with a relatively high health insurance coverage seem to �e �est options to improve access to DAA therapy [139] . Accessi�ility to DAAs, though, �y itself is a super� health achievement, still alone might not be sufficient to mitigate the �urden of HCV infection. A further challenge is continued transmission of HCV infection in high-ris�� population specially injecting drug users (IDUs) as the major reservoir of HCV infection [133, 137, 139] . Considering the fact that most of these infections remain undiagnosed, unidentified HCV-infected IDUs are potential sources for the spread of HCV infection in the society [133, [139] [140] [141] . While, silent introduction of HCV infection into the community is a serious threat to the national effort to eliminate HCV infection, a threat that will increase with time. Therefore, timely diagnosis of HCV-infected patients through ris��-�ased screening is of the greatest importance [126, 133, 137] . Screening of �lood donations for hepatitis C initiated in the early 1990s has remar��a�ly reduced the ris�� of HCV transmission through �lood transfusion since then. Blood transfusion �efore the early 1990s was a major contri�utor to the HCV transmission, �ut today this ris�� has �ecome minute [142] . However, it is far, far more difficult to screen IDUs, those who most need ris�� assessment. Despite the remar��a�le advantages, the cultural o�jections hinder screening progress, resulting in low diagnosis rate and, consequently, persistent silent spread of infection. On the other hand, the stigma of injecting drug use ma��es recognition of all HCV-infected IDUs impossible or logistically difficult at best [133] . In addition, esta�lishment of HCV screening system with a specific focus on IDUs imposes high financial �urden on the health system. Given the treatment expenses and dependence of these expenses on the stage of liver disease, screening of all at-ris�� populations seems much more afforda�le in a long run. Overall, in addition to interrupting unrecognized transmission of HCV, a part of costs expended in the treatment sector will also �e saved with the prompt diagnosis and timely treatment of infected �ut asymptomatic patients [133, 143] . While this process would demand allocation of adequate �udgets and resources to integrate routine screening of high-ris�� population into national health programs.
As another solution, the coverage of needle and syringe exchange program should �e expanded to increase the daily access to fresh needles and syringes among IDUs [144] . However, this program has not �een very successful to control HCV transmission thus far, as the prevalence of HCV infection among IDUs is on the rise [139] . In fact, the overall focus on syringe sharing as the main vehicle for HCV spread has ta��en focus away from the other ris�� �ehaviors of IDUs such as the shared use of drug ampoules or the other injecting paraphernalia, engagement in high-ris�� sexual practices and the other drug-related harms [145] . These circumstances create a strong demand for precise surveillance of IDUs to o�tain a relia�le insight into ris�� �ehaviors of IDUs community, and su�sequently harm reduction interventions should �e tailored to the common ris�� �ehaviors among IDUs to mitigate the ris�� of HCV transmission. In addition, raising general awareness of HCV infection, diagnosis and treatment through pu�lic education should �e the core activity of any harm reduction intervention, as the root cause of failure in control of HCV infection has �een lac�� of awareness among young drug ta��ers [133, 141, 146] . The growing num�er of IDUs and the relatively young age distri�ution of HCV-infected IDUs have evo��e huge attention and provided a good opportunity to drive down the increasing trend of HCV-related mortality in near future through timely interventions and appropriate treatment [139, 147] . The changes in HCV genotype distri�ution attri�uted to injecting drug use is another challenge in eliminating HCV infection. The changes in genotype distri�ution are so slight as to �e unnoticea�le �ut can have a deep impact on the epidemiology of HCV infection in a long run. These changes merit further attention if we want to properly manage the future �urden of HCV infection. Glo�ally, the most prevalent genotype is 1 (46%), followed �y 3 (22%), 2 (13%) and 4 (13%) [35, 137] . Over the last decade, however, a gradual decrease in the prevalence of genotype 1 and an increase in genotype 3 have �een reported due to some changes in the route of transmission, ris�� factors, source of infection, human migration flow, and age distribution [148, 149] . Blood transfusion �efore 1990 was the most important contri�utor to the spread of HCV, which has �een reflected in the predominance of genotype 1 among older individuals [149, 150] . In fact, screening for hepatitis C made �lood transfusion remar��a�ly safe since 1990s, paving the way for a gradual increase in the prevalence of genotype 3, which is mostly transmitted �y IDU [148] [149] [150] . In recent years, IDU has �ecome the main source of HCV transmission [35, 137, 144, 145] . Glo�ally, the estimated num�er of HCV-infected IDUs is up to 10.0 million (6.0-15.2 million), -15.2 million), 15.2 million), most of whom are young [35, 139, 144, 147, 151] . Meanwhile, the most common ris�� �ehavior of IDUs, syringe sharing, is more frequent among young drug injectors than in experienced and long-term injectors [152] , amplifying the transmission of HCV among young IDUs population and favoring the continuous increase of HCV genotype 3. In addition to the change in the route of HCV transmission, the ongoing civil strife in the Middle East and the active migration flow from India, Afghanistan and Pa��istan, where su�type 3a is endemic, have fuelled the increasing prevalence of genotype 3 [148] . On the other hand, death of elderly HCV carriers is slowly driving down the prevalence of HCV genotype 1. These changes in genotype distri�ution have profound effects on the prevalence of HCV infection, response to antiviral therapy, cost and duration of treatment, and future �urden of HCV infection. Given the higher rates of sustained virological response (SVR) to IFN-�ased therapy, the first-line therapy in lowand middle-income countries, in patients with HCV genotype 3 as compared to genotype 1 [149] , an increase in the prevalence of genotype 3 beneficially affects the treatment course �oth in terms of duration and in terms of cost and brings high benefits on an individual level. However, this increase would impose a greater ris�� on a population level. In reality the rising prevalence of HCV infection along with the continuous increase in the number of IDUs outweigh this benefit. The disastrous interacting epidemics of HCV infection and IDU are har�inger of a forthcoming pu�lic health dilemma, presenting a serious challenge to control transmission of HCV infection. On the other hand, high prevalence of HCV infection among young IDUs is a cause for concern, paving the way for rapid spread of HCV in the community. The old story of hepatitis C has gotten a new scenario. The emergence of IDU as the main ris�� factor for transmission of HCV is a surrogate in this new scenario. If this scenario is to continue, the emergence of an uncontrolla�le epidemic of hepatitis C will �e expected in the near future.
CONCLUSION
The glo�al community has always �een concerned a�out the future �urden of HCV infection. Although action on this concern has started many years ago with great hopes to eliminate HCV infection, the success remains elusive and will �ecome even more elusive if the current HCV management paradigm is to �e continued. We �elieve that it is now time to reconsider the wisdom of the current management strategies, admit failure, and act with all the strength. If we want to succeed in eliminating HCV infection, a more integrated international effort will �e required, involving health policy ma��ers, healthcare practitioners, pu�lic health organizations, antiviral drug manufacturers, health insurance companies, and all major sta��eholders. In addition, effective prevention, comprehensive screening programs with a specific focus on high-risk population, accessibility to the new anti-HCV treatment regimens and pu�lic education should �e considered as the top priorities of any health policy decision to eliminate HCV infection. While waiting for a solution, prevalence of HCV infection continues to increase. If we do not want to encounter another uncontrolla�le pu�lic health dilemma, the time to act is now, tomorrow will �e very late.
